Medicinal cannabis, Patient access in South Australia
SA Health is committed to ensuring South Australian consumers have access to the optimal range of treatments and services to promote the best health outcomes for patients and the community.
Patients in South Australia can access medicinal cannabis medicines as a result of federal legislative changes which came into effect in November 2016.
The State Government has released a patient access pathway to clarify access.
Importantly, medical practitioners must notify or apply for approval to the Commonwealth Department of Health (PDF 201KB) to supply and where necessary import, an unregistered medicinal cannabis product.
To consider whether medicinal cannabis is an appropriate treatment option, a specialist medical practitioner, in discussion with their patient, considers the clinical information and evidence for medicinal cannabis in the condition to be treated.
About the patient access pathway
A patient access pathway (PDF 153KB) for medicinal cannabis has been developed following consultation with stakeholders, including medical professionals, health practitioner organisations, consumers and health consumer groups, and industry.Under the pathway, patients in South Australia can be supplied medicinal cannabis products prescribed by their medical specialist and dispensed by a pharmacist.
Existing South Australian Controlled Substances legislation that regulates the prescribing and supply of Schedule 8 medicines in South Australia applies to Schedule 8 medicinal cannabis drugs.
A section 18A authority is only required for treatment longer than 2 months, or before commencing treatment where the person is already prescribed a Schedule 8 drug (for a period exceeding 2 months) and for any person the medical practitioner reasonably believes to be dependent on drugs.
A specialist medical practitioner is recognised by AHPRA as a specialist in the management of the disease being treated.
A section 18A authority is not required for patients:
- aged 70 years or older
- who are Notified Palliative Care Patients
- who are not drug dependent, for regular use for a period of less than 2 months.
Applications for authority to prescribe Schedule 8 medicinal cannabis products may be referred to an expert clinical panel within SA Health for advice on a case by case basis.
One cannabis derivative, cannabidiol in preparations for therapeutic use containing 2% or less of other cannabinoids found in cannabis, is a Schedule 4 medicine. This means the total cannabinoids in the product must be at least 98% cannabidiol to be in Schedule 4. Supply of Schedule 4 cannabidiol medicines requires a prescription from a medical practitioner, and Commonwealth approval or notification.An authority for purposes of South Australian Controlled Substances legislation is not required to prescribe Schedule 4 cannabidiol medicines.
Approval to prescribe
To apply for approval to prescribe a Schedule 8 medicinal cannabis drug or to discuss authority requirements and exemptions in South Australia contact:
Phone: 1300 652 584
Fax: 1300 658 447
Phone: 1800 020 653
The medicinal use of cannabis in clinical treatment is subject to ongoing discussion and investigation by health professionals.There is some clinical evidence (PDF 168KB) for use of cannabis and derivatives in severe chronic conditions unresponsive to existing treatments, however further research and development is progressing into the safety and efficacy of medicinal cannabis products, and to establish their role in clinical use.
Medicinal cannabis products
Cannabis for medical use is regulated as a medicine in Australia. Medicinal cannabis products, with the exception of Sativex®, are not included on the Australian Register of Therapeutic Goods (ARTG) which means they have not been subject to the same standards of safety and efficacy that apply to other prescription medicines in Australia. Unregistered medicines, including unregistered medicinal cannabis products can be legally imported on authorisation from the Therapeutic Goods Administration (TGA) and Office of Drug Control (ODC).
Progressing a patient access pathway for medicinal cannabis provides clarity for patients, doctors and other health practitioners about access in South Australia. It also provides certainty to potential new medicinal cannabis industry stakeholders.
For more information about the patient access pathway to medicinal cannabis in South Australia:
Medicines and Technology Programs
Department of Health and Ageing
Phone: (08) 8226 6169
For information about industry development support in South Australia: